<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042298</url>
  </required_header>
  <id_info>
    <org_study_id>Pro9646</org_study_id>
    <nct_id>NCT04042298</nct_id>
  </id_info>
  <brief_title>Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy</brief_title>
  <official_title>Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansas State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansas State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate potential differences in vascular function
      between patients receiving 5-Fluorouracil (5-FU) chemotherapy, patients receiving
      chemotherapies other than 5-FU, cancer survivors who were treated with 5-FU, and an age and
      sex matched control. 5-FU is the third most commonly administered chemotherapeutic agent and
      its use is associated with the second most occurrences of cardiotoxicity. Despite the known
      cardiotoxic effects of 5-FU, it's effects on the human vasculature are not well understood.

      To achieve the goals of this project Laser Doppler flowmetry (LDF) will be used to assess
      blood flow within the skin microcirculation of the forearm in cancer patients who have
      received 5-Fluoruracil within the past 30 days (Experimental Group), cancer patients
      receiving radiotherapy and/or chemotherapy other than 5-Fluorouracil, and an age and sex
      matched control (Control Group). LDF utilizes a small (~3 cm) non-invasive sensor placed on
      the skin. The sensor shines light into the skin, and upon contact with red blood cells
      (RBCs), the light is reflected and scattered. This information is used to evaluate
      microvascular blood flow and has previously been used in clinical populations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although cancer continues to be one of the leading causes of death each year, advancements in
      cancer treatments and detection have improved patient prognosis across a large number of
      cancer types. This trend of improved survival rates has made apparent the significant risk of
      chemotherapy on the cardiovascular system in such a way that cardiotoxicity has become a
      prime concern in cancer survivors. Indeed, cardiotoxic events have been related to numerous
      chemotherapy types, including the commonly used 5-Fluorouracil (5-FU). 5-FU is the third most
      commonly administered form of chemotherapy used in the treatment of solid malignancies.
      Despite undeniable effectiveness in treating cancer, administration of 5-FU is associated
      with the second highest incidence of cardiotoxicity out of all chemotherapeutic agents.

      Such cardiotoxic manifestations typically appear in the form of chest pain, angina during
      rest and/or exertion, and acute coronary syndromes, however, other events such as arrythmias,
      myocarditis, pericarditis, heart failure, or even death have been reported following 5-FU
      administration. While multiple mechanisms are believed to lead to 5-FU cardiotoxicity, the
      effects 5-FU has on the vasculature seem to be of particular importance. Initial findings
      suggest these drugs have a direct toxic effect on the vascular endothelium and smooth muscle,
      likely through increases in reactive oxygen species (ROS). ROS are known to adversely affect
      endothelium independent and dependent factors which influence vascular tone. Along with
      increased ROS, decreases in antioxidant capacity following 5-FU therapy lead to increased
      vasospasms and altered vasodilator/constrictor responses. Indeed, both coronary artery
      vasospasms and brachial artery vasoconstriction have been found to occur in some groups
      directly after injection of 5-FU.

      Although the primary signaling pathways for 5-FU induced cardiotoxicity are well documented,
      many of these studies have been conducted in animal models. Previous work has demonstrated
      substantial vascular dysfunction in current cancer patients undergoing adjuvant systematic
      chemotherapy when compared to healthy controls, however, alike investigations specifically
      focused on vascular dysfunction in patients receiving 5-FU have yet to be conducted. To
      investigate such mechanisms, microvascular reactivity will be measured with laser Doppler
      flowmetry combined with iontophoresis of acetylcholine in cancer patients currently
      undergoing treatment with 5-Fluorouracil, patients receiving chemotherapy treatments other
      than 5-Fluorouracil, cancer survivors previously treated with 5-Fluorouracil, and age and sex
      matched controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous (skin) blood flow (%) following administration of vasoactive substances</measure>
    <time_frame>1 day</time_frame>
    <description>Measured once in each group following administration of vasodilatory (Acetylcholine) and vasoconstrictive (Norepinepherine or Phenylephrine) substances.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial artery flow mediated dilation (FMD)</measure>
    <time_frame>1 day</time_frame>
    <description>Measured once in each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure</measure>
    <time_frame>1 day</time_frame>
    <description>Systolic, diastolic, and mean arterial pressure will be measured continuously over the course of the visit for each group.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>5-Fluorouracil Toxicity</condition>
  <arm_group>
    <arm_group_label>5-FU Chemotherapy (Experimental)</arm_group_label>
    <description>Comprised of newly diagnosed cancer patients 21 years or older who have received 5-FU chemotherapy within the past 30 days or are scheduled to receive 5-FU chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-5-FU Chemotherapy (Sub-Control)</arm_group_label>
    <description>Comprised of newly diagnosed cancer patients 21 years or older who have received chemotherapy other than 5-FU within the past 30 days or are scheduled to receive chemotherapy other than 5-FU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age/Sex matched Control (Control)</arm_group_label>
    <description>Age, biological sex, and prior health history (excluding cancer diagnosis) matched control for cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-FU Chemotherapy Cancer Survivor (Survivor)</arm_group_label>
    <description>Cancer survivors who have not received cancer therapy during the past year but previously received 5-Fluorouracil chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arterial blood pressure</intervention_name>
    <description>Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).</description>
    <arm_group_label>5-FU Chemotherapy (Experimental)</arm_group_label>
    <arm_group_label>5-FU Chemotherapy Cancer Survivor (Survivor)</arm_group_label>
    <arm_group_label>Age/Sex matched Control (Control)</arm_group_label>
    <arm_group_label>Non-5-FU Chemotherapy (Sub-Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin microcirculatory blood flow</intervention_name>
    <description>Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.</description>
    <arm_group_label>5-FU Chemotherapy (Experimental)</arm_group_label>
    <arm_group_label>5-FU Chemotherapy Cancer Survivor (Survivor)</arm_group_label>
    <arm_group_label>Age/Sex matched Control (Control)</arm_group_label>
    <arm_group_label>Non-5-FU Chemotherapy (Sub-Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brachial artery blood flow</intervention_name>
    <description>A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.</description>
    <arm_group_label>5-FU Chemotherapy (Experimental)</arm_group_label>
    <arm_group_label>5-FU Chemotherapy Cancer Survivor (Survivor)</arm_group_label>
    <arm_group_label>Age/Sex matched Control (Control)</arm_group_label>
    <arm_group_label>Non-5-FU Chemotherapy (Sub-Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood draw</intervention_name>
    <description>A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.</description>
    <arm_group_label>5-FU Chemotherapy (Experimental)</arm_group_label>
    <arm_group_label>5-FU Chemotherapy Cancer Survivor (Survivor)</arm_group_label>
    <arm_group_label>Age/Sex matched Control (Control)</arm_group_label>
    <arm_group_label>Non-5-FU Chemotherapy (Sub-Control)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples (5-7 mL) from the antecubital vein or a vein in the back of the hand
      will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the
      experimental visit. These blood samples will be analyzed for the presence of reactive oxygen
      species and inflammatory markers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed cancer patients who have received (or are scheduled to receive) 5-FU
        chemotherapy within the past 30 days (n=26) will enter the study soon after initiation of
        treatment. Newly diagnosed cancer patients receiving cancer treatment other than 5-FU
        (n=26; chemotherapy, radiotherapy, etc.) will enter into the study soon after initiation of
        treatment. Cancer survivors (n=26) who have previously received 5-FU but not within the
        year proceeding enrollment will be entered into the study. Age, sex, and health (n=26;
        excluding cancer) matched controls will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give voluntary consent to participate in the study

          -  (Group 1) Current cancer treatment includes 5-FU

          -  (Group 2) Current cancer treatment does not include 5-FU

          -  (Group 3) Cancer survivor previously treated with 5-FU but has not received cancer
             treatment in the year proceeding enrollment.

          -  (Group 4) Age, sex, and health matched (excluding cancer) control for Group 1

        Exclusion Criteria:

          -  (Groups 1, 2, and 4) Have received cancer treatment outside of the past year

          -  Not met above criteria

          -  Pregnant, breastfeeding, or planning to become pregnant

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carl J Ade, PhD</last_name>
    <phone>785-532-1127</phone>
    <email>cade@ksu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steve T Hammond</last_name>
    <phone>7402020300</phone>
    <email>sthammond1@ksu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lafene Health Center</name>
      <address>
        <city>Manhattan</city>
        <state>Kansas</state>
        <zip>66502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl J Ade, Ph.D.</last_name>
      <phone>785-532-1127</phone>
      <email>cade@k-state.edu</email>
    </contact>
    <contact_backup>
      <last_name>Steve T Hammond</last_name>
      <phone>740-202-0300</phone>
      <email>sthammond1@ksu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47. doi: 10.1016/j.jacc.2009.02.050. Review.</citation>
    <PMID>19520246</PMID>
  </reference>
  <reference>
    <citation>Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. doi: 10.1177/1758835918780140. eCollection 2018. Review.</citation>
    <PMID>29977352</PMID>
  </reference>
  <reference>
    <citation>Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003 Dec;42(6):1075-81. Epub 2003 Oct 27. Review.</citation>
    <PMID>14581295</PMID>
  </reference>
  <reference>
    <citation>Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014 Sep 4;15:47. doi: 10.1186/2050-6511-15-47. Review.</citation>
    <PMID>25186061</PMID>
  </reference>
  <reference>
    <citation>Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991 Mar;12(3):468-70.</citation>
    <PMID>2040332</PMID>
  </reference>
  <reference>
    <citation>SÃ¼dhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004 Apr;15(4):661-4.</citation>
    <PMID>15033676</PMID>
  </reference>
  <reference>
    <citation>Sutterfield SL, Caldwell JT, Post HK, Lovoy GM, Banister HR, Ade CJ. Lower cutaneous microvascular reactivity in adult cancer patients receiving chemotherapy. J Appl Physiol (1985). 2018 Oct 1;125(4):1141-1149. doi: 10.1152/japplphysiol.00394.2018. Epub 2018 Aug 9.</citation>
    <PMID>30091663</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kansas State University</investigator_affiliation>
    <investigator_full_name>Carl Ade, M.S., Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

